Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma

Biomedicine and Pharmacotherapy

Volumn 84, Issue , 2016, Pages 583-591

  Zhang, Tong ^a   Liu, Wei ^a   Zeng, Xian cheng ^b   Jiang, Nan ^a   Fu, Bin sheng ^a   Guo, Y ^a   Yi, Hui ming ^a   Li, Hua ^a   Zhang, Qi ^a   Chen, Wen jie ^a   Chen, Gui hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG SECOND PROVINCIAL GENERAL HOSPITAL   (China)

Author keywords

Angiogenesis; Hepatocellular carcinoma; microRNA; VEGF

Indexed keywords

BETA CATENIN; METASTASIS IN COLON CANCER 1 PROTEIN; MICRORNA; MICRORNA 338 3P; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; 3' UNTRANSLATED REGION; CONDITIONED MEDIUM; CTNNB1 PROTEIN, HUMAN; MACC1 PROTEIN, HUMAN; MIRN338 MICRORNA, HUMAN; TRANSCRIPTION FACTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; ANGIOGENESIS; ARTICLE; CANCER TISSUE; CELL ASSAY; CHORIOALLANTOIC MEMBRANE ASSAY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; TRANSWELL ASSAY; UPREGULATION; ANIMAL; BINDING SITE; CELL MOTION; CHICK EMBRYO; CHORIOALLANTOIS; CONDITIONED MEDIUM; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION;

3' UNTRANSLATED REGIONS; ANIMALS; BETA CATENIN; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84988969579     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.09.056     Document Type: Article

References (39)

1. [1] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA: Cancer J. Clin. 61:2 (2011), 69–90.
2. [2] Siegel, R., Naishadham, D., Jemal, A., Cancer statistics. CA: Cancer J. Clin. 62:1 (2012), 10–29.
3. [3] Siegel, R., Naishadham, D., Jemal, A., Cancer statistics. CA: Cancer J. Clin. 63:1 (2013), 11–30.
4. [4] Yang, J.D., Roberts, L.R., Hepatocellular carcinoma: a global view. Nat. Rev. Gastroenterol. Hepatol. 7:8 (2010), 448–458.
5. [5] Gupta, G.P., Massague, J., Cancer metastasis: building a framework. Cell 127:4 (2006), 679–695.
6. [6] Tung-Ping Poon, R., Fan, S.T., Wong, J., Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann. Surg. 232:1 (2000), 10–24.
7. [7] Budhu, A., Wang, X.W., The role of cytokines in hepatocellular carcinoma. J. Leukoc. Biol. 80:6 (2006), 1197–1213.
8. [8] Dvorak, H.F., Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20:21 (2002), 4368–4380.
9. [9] Hisai, H., Kato, J., Kobune, M., Murakami, T., Miyanishi, K., Takahashi, M., Yoshizaki, N., Takimoto, R., Terui, T., Niitsu, Y., Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin. Cancer Res. 9:13 (2003), 4852–4859.
10. [10] Yu, D., Sun, X., Qiu, Y., Zhou, J., Wu, Y., Zhuang, L., Chen, J., Ding, Y., Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin. Cancer Res. 13:13 (2007), 3814–3824.
11. [11] Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100:1 (2000), 57–70.
12. [12] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
13. [13] Hernandez-Gea, V., Toffanin, S., Friedman, S.L., Llovet, J.M., Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144:3 (2013), 512–527.
14. [14] Budhu, A., Jia, H.L., Forgues, M., Liu, C.G., Goldstein, D., Lam, A., Zanetti, K.A., Ye, Q.H., Qin, L.X., Croce, C.M., Tang, Z.Y., Wang, X.W., Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47:3 (2008), 897–907.
15. [15] Hou, J., Lin, L., Zhou, W., Wang, Z., Ding, G., Dong, Q., Qin, L., Wu, X., Zheng, Y., Yang, Y., Tian, W., Zhang, Q., Wang, C., Zhang, Q., Zhuang, S.M., Zheng, L., Liang, A., Tao, W., Cao, X., Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19:2 (2011), 232–243.
16. [16] Xiong, Y., Fang, J.H., Yun, J.P., Yang, J., Zhang, Y., Jia, W.H., Zhuang, S.M., Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 51:3 (2010), 836–845.
17. [17] Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:2 (2004), 281–297.
18. [18] Ding, J., Huang, S., Wu, S., Zhao, Y., Liang, L., Yan, M., Ge, C., Yao, J., Chen, T., Wan, D., Wang, H., Gu, J., Yao, M., Li, J., Tu, H., He, X., Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat. Cell Biol. 12:4 (2010), 390–399.
19. [19] Lujambio, A., Lowe, S.W., The microcosmos of cancer. Nature 482:7385 (2012), 347–355.
20. [20] Yang, Z., Miao, R., Li, G., Wu, Y., Robson, S.C., Yang, X., Zhao, Y., Zhao, H., Zhong, Y., Identification of recurrence related microRNAs in hepatocellular carcinoma after surgical resection. Int. J. Mol. Sci. 14:1 (2013), 1105–1118.
21. [21] Esquela-Kerscher, A., Slack, F.J., Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer 6:4 (2006), 259–269.
22. [22] Yang, P., Li, Q.J., Feng, Y., Zhang, Y., Markowitz, G.J., Ning, S., Deng, Y., Zhao, J., Jiang, S., Yuan, Y., Wang, H.Y., Cheng, S.Q., Xie, D., Wang, X.F., TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 22:3 (2012), 291–303.
23. [23] Huang, X.H., Chen, J.S., Wang, Q., Chen, X.L., Wen, L., Chen, L.Z., Bi, J., Zhang, L.J., Su, Q., Zeng, W.T., miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J. Pathol. 225:3 (2011), 463–472.
24. [24] Sun, K., Deng, H.J., Lei, S.T., Dong, J.Q., Li, G.X., miRNA-338-3p suppresses cell growth of human colorectal carcinoma by targeting smoothened. World J. Gastroenterol. 19:14 (2013), 2197–2207.
25. [25] Stein, U., Walther, W., Arlt, F., Schwabe, H., Smith, J., Fichtner, I., Birchmeier, W., Schlag, P.M., MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat. Med. 15:1 (2009), 59–67.
26. [26] Qiu, J., Huang, P., Liu, Q., Hong, J., Li, B., Lu, C., Wang, L., Wang, J., Yuan, Y., Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J. Transl. Med., 9, 2011, 166.
27. [27] Dvorak, H.F., Brown, L.F., Detmar, M., Dvorak, A.M., Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:5 (1995), 1029–1039.
28. [28] Liu, Y., Poon, R.T., Li, Q., Kok, T.W., Lau, C., Fan, S.T., Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 65:9 (2005), 3691–3699.
29. [29] Poon, R.T., Ng, I.O., Lau, C., Zhu, L.X., Yu, W.C., Lo, C.M., Fan, S.T., Wong, J., Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann. Surg. 233:2 (2001), 227–235.
30. [30] Fu, X., Tan, D., Hou, Z., Hu, Z., Liu, G., Ouyang, Y., Liu, F., The effect of miR-338-3p on HBx deletion-mutant (HBx-d382) mediated liver-cell proliferation through CyclinD1 regulation. PLoS One, 7(8), 2012, e43204.
31. [31] Arlt, F., Stein, U., Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int. J. Biochem. Cell Biol. 41:12 (2009), 2356–2359.
32. [32] Kaposi-Novak, P., Lee, J.S., Gomez-Quiroz, L., Coulouarn, C., Factor, V.M., Thorgeirsson, S.S., Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 116:6 (2006), 1582–1595.
33. [33] Stein, U., Smith, J., Walther, W., Arlt, F., MACC1 controls met: what a difference an Sp1 site makes. Cell Cycle 8:15 (2009), 2467–2469.
34. [34] Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., Korinek, V., Roose, J., Destree, O., Clevers, H., XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 86:3 (1996), 391–399.
35. [35] Behrens, J., von Kries, J.P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., Birchmeier, W., Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382:6592 (1996), 638–642.
36. [36] Chang, C.J., Yang, J.Y., Xia, W., Chen, C.T., Xie, X., Chao, C.H., Woodward, W.A., Hsu, J.M., Hortobagyi, G.N., Hung, M.C., EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 19:1 (2011), 86–100.
37. [37] Deng, J., Miller, S.A., Wang, H.Y., Xia, W., Wen, Y., Zhou, B.P., Li, Y., Lin, S.Y., Hung, M.C., beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2:4 (2002), 323–334.
38. [38] Lee, J.M., Kim, I.S., Kim, H., Lee, J.S., Kim, K., Yim, H.Y., Jeong, J., Kim, J.H., Kim, J.Y., Lee, H., Seo, S.B., Kim, H., Rosenfeld, M.G., Kim, K.I., Baek, S.H., RORalpha attenuates Wnt/beta-catenin signaling by PKCalpha-dependent phosphorylation in colon cancer. Mol. Cell 37:2 (2010), 183–195.
39. [39] Wang, L., Heidt, D.G., Lee, C.J., Yang, H., Logsdon, C.D., Zhang, L., Fearon, E.R., Ljungman, M., Simeone, D.M., Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell 15:3 (2009), 207–219.